biostudies-literatureShah SNIDA NIH HHSNational Institute on Drug Abuse2457-2461https://www.ebi.ac.uk/biostudies/studies/S-EPMC10940736biostudies-literatureUnknown78(10)<h4>Objectives</h4>The incidence of Serratia endocarditis is increasing, yet optimal treatment has not been defined. Our objective was to investigate the outcomes of patients with Serratia endocarditis by treatment strategy.<h4>Methods</h4>We reviewed adult patients with definitive Serratia endocarditis at two independent health systems between July 2001 and April 2023. Combination therapy was defined as receipt of ≥2 in vitro active agents for ≥72 h.<h4>Results</h4>Seventy-five patients were included; 64% (48/75) were male and 85% (64/75) were people who inject drugs. Compared with monotherapy, receipt of combination therapy was associated with lower rates of microbiological failure (0% versus 15%, P = 0.026) and 90 day all-cause mortality (11% versus 31%, P = 0.049). Antimicrobial discontinuation due to an adverse event was more common among patients receiving combination therapy compared with monotherapy (36% versus 8%, P = 0.058).<h4>Conclusions</h4>In the largest series of Serratia endocarditis to date, combination antibiotic treatment was associated with improved outcomes. However, larger, prospective studies are warranted.The Journal of antimicrobial chemotherapySerratia endocarditis: antimicrobial management strategies and clinical outcomes.PMC10940736K23DA049946K23 DA049946McCrary MShields RKDavis MWSchranz AJShah STopal JSlain DMarx AClarke LStoner BJfalseSerratia endocarditis: antimicrobial management strategies and clinical outcomes.<h4>Objectives</h4>The incidence of Serratia endocarditis is increasing, yet optimal treatment has not been defined. Our objective was to investigate the outcomes of patients with Serratia endocarditis by treatment strategy.<h4>Methods</h4>We reviewed adult patients with definitive Serratia endocarditis at two independent health systems between July 2001 and April 2023. Combination therapy was defined as receipt of ≥2 in vitro active agents for ≥72 h.<h4>Results</h4>Seventy-five patients were included; 64% (48/75) were male and 85% (64/75) were people who inject drugs. Compared with monotherapy, receipt of combination therapy was associated with lower rates of microbiological failure (0% versus 15%, P = 0.026) and 90 day all-cause mortality (11% versus 31%, P = 0.049). Antimicrobial discontinuation due to an adverse event was more common among patients receiving combination therapy compared with monotherapy (36% versus 8%, P = 0.058).<h4>Conclusions</h4>In the largest series of Serratia endocarditis to date, combination antibiotic treatment was associated with improved outcomes. However, larger, prospective studies are warranted.2023-01-01T00:00:00Z2023 Oct2026-03-17T16:15:18.625Z2025-08-21T09:50:33.818ZS-EPMC109407363756387610.1093/jac/dkad254